Condition hub
PCOS and GLP-1
Polycystic Ovary Syndrome (PCOS) affects an estimated 1 million diagnosed UK women, with a further 2 to 3 million undiagnosed. It is fundamentally a condition of insulin resistance plus androgen excess, with downstream effects on weight, fertility and metabolic health. GLP-1 medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) act directly on the insulin-resistance pathway, which is why UK clinicians are increasingly interested in them for PCOS. NHS prescribing for PCOS is currently off-label, so the route is private. PeptideClear publishes editorial commentary; prescribing decisions sit with a UK-licensed clinician.
Why GLP-1 helps in PCOS
- · Improved insulin sensitivity. GLP-1 increases insulin response and reduces hepatic glucose output. PCOS-related insulin resistance often falls.
- · Modest weight loss restores ovulatory cycles in many women with weight-driven PCOS. 5-10% weight loss is the typical threshold.
- · Reduced testosterone in many PCOS patients on GLP-1 (secondary to weight loss and insulin improvement). Hirsutism and acne can improve over months, not weeks.
- · Blood pressure and lipid profile typically improve, reducing long-term cardiovascular risk that PCOS adds.
UK access route for PCOS
- · NHS Mounjaro (NICE TA1026) is licensed for weight management with comorbidity. PCOS is not currently listed as a qualifying comorbidity. Type 2 diabetes secondary to PCOS may qualify; insulin resistance alone usually does not.
- · Private clinic route (Numan, Voy, Manual, Juniper) prescribes off-label for PCOS-driven weight where BMI fits clinic criteria.
- · Pharmacy-direct (Phlo, Pharmacy2U, SimplyMeds) typically requires BMI 30+ regardless of underlying PCOS. PCOS is not a fast-track route on pharmacy questionnaires.
- · Specialist gynaecologist or endocrinologist is the most coordinated route if you also need fertility planning, hormonal management, or metformin alongside GLP-1.
Fertility, conception, breastfeeding
- · Both Mounjaro and Wegovy are contraindicated in pregnancy.
- · UK guidance: stop GLP-1 medication at least 2 months before trying to conceive (Mounjaro), or 2 months for Wegovy. Some clinics recommend 3 months as a buffer.
- · Mounjaro may reduce the effectiveness of oral hormonal contraceptives because of delayed gastric emptying. The Eli Lilly PIL recommends adding a barrier method or switching to a non-oral contraceptive when starting Mounjaro and for 4 weeks after each dose increase.
- · If you become pregnant unexpectedly while on a GLP-1, contact your prescriber the same day. Stopping the medication is straightforward; the planning conversation is the priority.
Ready to buy
Find a UK GLP-1 clinic or pharmacy
GMC-registered prescribers compared by price, consultation type, and refund policy. Editorial only. We do not prescribe.